Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely a Possibility’; Alto’s Precision Psychiatry Platform Under Pressure; MAPS Boosts Funding for Mass. Psychedelics Ballot Question Post published:October 25, 2024 Post category:Psychedelic Bulletin/Pα+
Natural Medicine Advisory Bulletin 14 Post published:October 24, 2024 Post category:Colorado Natural Medicine Advisory Bulletin
Psychedelics Take Centre Stage in Massachusetts’ Local Media Post published:October 21, 2024 Post category:Analysis/News
Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug Success; Kasvu Therapeutics Is Developing Psychoplastogens With a TrkB Twist Post published:October 18, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme Post published:October 11, 2024 Post category:Psychedelic Bulletin/Pα+
Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms: An Interview with Nassir Ghaemi Post published:October 10, 2024 Post category:Analysis/News
Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos Post published:October 4, 2024 Post category:Psychedelic Bulletin/Pα+
The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits Post published:September 30, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more… Post published:September 27, 2024 Post category:Psychedelic Bulletin/Pα+